Therapeutic methods using anti-CD200 antibodies

Patent metadata

Field	Value
Publication number	US-9862767-B2
Application number	US-201514739862-A
Country	US
Kind code	B2
Filing date	Jun 15, 2015
Priority date	Feb 11, 2010
Publication date	Jan 9, 2018
Grant date	Jan 9, 2018

Abstract

The present disclosure relates to anti-CD200 antibodies and to use of the antibodies in methods for treating autoimmune disorders and cancer. Also featured are biomarkers for use in selecting or prescribing a treatment modality for a patient with an autoimmune disorder and/or cancer. In addition, the disclosure features methods of treatment using an anti-CD200 antibody in combination with one or more additional therapeutic agents such as an anti-CD20 therapeutic agent.

First claim

The invention claimed is:

1. A method for treating a human afflicted with a cancer, the method comprising administering to the human an anti-CD200 antibody, or a CD200-binding fragment thereof, in an amount that is sufficient to treat the cancer, wherein the cancer is resistant, or is suspected of being resistant, to therapy with an anti-CD20 antibody, wherein the anti-CD200 antibody, or CD200-binding fragment thereof, contains one of the following paired set of CDRs:
(i) a HCDR1 comprising the amino acid sequence: GFNIKDYYMH (SEQ ID NO:10); a HCDR2 comprising the amino acid sequence: WIDPENGDTKYAPKFQG (SEQ ID NO:11); a HCDR3 comprising the amino acid sequence: KNYYVSNYNFFDV (SEQ ID NO:12); a LCDR1 comprising the amino acid sequence: SASSSVRYMY (SEQ ID NO:13); a LCDR2 comprising the amino acid sequence: DTSKLAS (SEQ ID NO:14); and a LCDR3 comprising the amino acid sequence: FQGSGYPLT (SEQ ID NO:15);
(ii) a HCDR1 comprising the amino acid sequence: GFNIKDYYIH (SEQ ID NO:16); a HCDR2 comprising the amino acid sequence: WIDPEIGATKYVPKFQG (SEQ ID NO:17); a HCDR3 comprising the amino acid sequence: LYGNYDRYYAMDY (SEQ ID NO:18); a LCDR1 comprising the amino acid sequence: KASQNVRTAVA (SEQ ID NO:19); a LCDR2 comprising the amino acid sequence: LASNRHT (SEQ ID NO:20); and a LCDR3 comprising the amino acid sequence: LQHWNYPLT (SEQ ID NO:21);
(iii) a HCDR1 comprising the amino acid sequence: GYSFTDYIIL (SEQ ID NO:22); a HCDR2 comprising the amino acid sequence: HIDPYYGSSNYNLKFKG (SEQ ID NO:23); a HCDR3 comprising the amino acid sequence: SKRDYFDY (SEQ ID NO:24); a LCDR1 comprising the amino acid sequence: KASQDINSYLS (SEQ ID NO:25); a LCDR2 comprising the amino acid sequence: RANRLVD (SEQ ID NO:26); and a LCDR3 comprising the amino acid sequence: LQYDEFPYT (SEQ ID NO:27);
(iv) a HCDR1 comprising the amino acid sequence: GYTFTEYTMH (SEQ ID NO:28); a HCDR2 comprising the amino acid sequence: GVNPNNGGALYNQKFKG (SEQ ID NO:29); a HCDR3 comprising the amino acid sequence: RSNYRYDDAMDY (SEQ ID NO:30); a LCDR1 comprising the amino acid sequence: KSSQSLLDIDEKTYLN (SEQ ID NO:31); a LCDR2 comprising the amino acid sequence: LVSKLDS (SEQ ID NO:32); and a LCDR3 comprising the amino acid sequence: WQGTHFPQT (SEQ ID NO:33); or
(v) a HCDR1 comprising the amino acid sequence: AFNIKDHYMH (SEQ ID NO:34); a HCDR2 comprising the amino acid sequence: WIDPESGDTEYAPKFQG (SEQ ID NO:35); a HCDR3 comprising the amino acid sequence: FNGYQALDQ (SEQ ID NO:36); a LCDR1 comprising the amino acid sequence: TASSSVSSSYLH (SEQ ID NO:37); a LCDR2 comprising the amino acid sequence: STSNLAS (SEQ ID NO:38); and a LCDR3 comprising the amino acid sequence: RQYHRSPPIFT (SEQ ID NO:39).

2. The method of claim 1 , wherein the cancer comprises cancer cells that express CD5.

3. The method of claim 1 , wherein the cancer is a liquid tumor.

4. The method of claim 3 , wherein the liquid tumor is a chronic lymphocytic leukemia or multiple myeloma.

5. The method of claim 4 , wherein the chronic lymphocytic leukemia is a B cell chronic lymphocytic leukemia.

6. The method of claim 1 , further comprising administering to the human an anti-CD20 therapeutic agent.

7. The method of claim 6 , wherein the anti-CD20 therapeutic agent is an anti-CD20 antibody or a CD20-binding fragment thereof.

8. The method of claim 7 , wherein the anti-CD20 antibody is rituximab, ofatumumab, TRU-015, veltuzumab, ocrelizumab, or AME-133v.

9. The method of claim 7 , wherein the anti-CD20 antibody, or CD20-binding fragment thereof, is conjugated to a toxin.

10. The method of claim 1 , wherein the anti-CD200 antibody, or CD200-binding fragment thereof, is a bispecific antibody comprising a first antigen combining site that binds to CD200 and a second antigen combining site that binds to CD20.

11. The method of claim 1 , wherein the anti-CD200 antibody, or CD200-binding fragment thereof, inhibits the interaction between CD200 and CD200R.

12. The method of claim 1 , wherein the anti-CD200 antibody, or CD200-binding fragment thereof, is murine, chimeric, humanized, or fully human.

13. The method of claim 1 , wherein the CD200-binding fragment is selected from the group consisting of a Fab fragment, a F(ab′) 2 fragment, a Fab′ fragment, an scFv fragment, a minibody, a diabody, or a triabody.

Assignees

• Alexion Pharma Inc

Inventors

• Rother Russell P
• Yan Yan

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• A61P35/02

  specific for leukemia · CPC title

• C07K16/2887

  against CD20 · CPC title

• A61K2039/505

  comprising antibodies · CPC title